person · Reporting owner

Pletcher Brett A

Disclosed activity across 2 companies

Tapewire entity: 15453
SEC CIK: 0001739307

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
CYTOKINETICS INCCYTK · Entity 3528	EVP, Chief Legal Officer	August 30, 2024	September 03, 2024
GILEAD SCIENCES, INC.GILD · Entity 405	EVP,Corp Affairs & Gen Counsel	June 10, 2022	June 14, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CYTOKINETICS INC

Report date August 30, 2024 · Filed September 03, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	33,140	Reported balance After 2024-08-30 transaction · row 1 1 source row Row 1 · 2024-08-30 · Grant · Acquired 33,140 · Balance 33,140 F1: Inducement grant comprised of restricted stock units ("RSUs") that are converted into shares of common stock on a 1:1 basis upon time based vesting. 40% of the RSUs vest on the 1-year anniversary of the grant date, an additional 40% of the RSUs vest on the 2-year anniversary of the grant date, and the remaining 20% of the RSUs vest on the 3-year anniversary of the grant date, in each case subject to the grantee's continued employment with the company.
Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $57.08 · Expires 2034-08-30	Direct	51,039	Reported balance After 2024-08-30 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-08-30 · Grant · Acquired 51,039 · Balance 51,039 F2: Inducement grant comprised of stock options to purchase shares of common stock subject to time lapse vesting. 25% of the stock options vest on the 1-year anniversary of the grant date and the remaining 75% of the stock options vest in equal monthly installments over the subsequent 3 years to the 1-year anniversary of the grant date, with each installment vesting subject to the grantee's continued employment with the company.

Filing footnotes · ownership attribution and instrument terms

F1: Inducement grant comprised of restricted stock units ("RSUs") that are converted into shares of common stock on a 1:1 basis upon time based vesting. 40% of the RSUs vest on the 1-year anniversary of the grant date, an additional 40% of the RSUs vest on the 2-year anniversary of the grant date, and the remaining 20% of the RSUs vest on the 3-year anniversary of the grant date, in each case subject to the grantee's continued employment with the company.

F2: Inducement grant comprised of stock options to purchase shares of common stock subject to time lapse vesting. 25% of the stock options vest on the 1-year anniversary of the grant date and the remaining 75% of the stock options vest in equal monthly installments over the subsequent 3 years to the 1-year anniversary of the grant date, with each installment vesting subject to the grantee's continued employment with the company.

GILEAD SCIENCES, INC.

Report date June 10, 2022 · Filed June 14, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	33,426	Ending reported balance After 2022-06-10 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2022-06-10 · Exercise / conversion · Acquired 782 · Balance 33,706 F1: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Row 2 · 2022-06-10 · Tax withholding · Disposed 280 · Balance 33,426
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	16,519	Reported balance After 2022-06-10 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-06-10 · Exercise / conversion · Disposed 782 · Balance 16,519 F1: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 10, 2018 Filed Aug 14, 2018 18:05 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionCommon Stock	1,070	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-18-025255 · form4.xml · nonDerivative · entry 1 Pletcher Brett A · CIK 0001739307 · EVP, Gen Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,101 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document
July 31, 2018 Filed Aug 2, 2018 21:15 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionRestricted Stock Unit · Derivative	2,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-18-024473 · form4.xml · derivative · entry 3 Pletcher Brett A · CIK 0001739307 · EVP, Gen Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,140 Underlying: Common Stock · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. Read SEC document
July 31, 2018 Filed Aug 2, 2018 21:15 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Tax withholdingCommon Stock	910	$77.83	$70,825.30	Disclosure SEC source: 0001127602-18-024473 · form4.xml · nonDerivative · entry 2 Pletcher Brett A · CIK 0001739307 · EVP, Gen Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,031 Read SEC document
July 31, 2018 Filed Aug 2, 2018 21:15 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionCommon Stock	2,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-18-024473 · form4.xml · nonDerivative · entry 1 Pletcher Brett A · CIK 0001739307 · EVP, Gen Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,941 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.